ArticleThe Journal of clinical endocrinology and metabolism2025
An NMR-Based Metabolic Signature to Identify Clinically Significant Prostate Cancer in Patients Undergoing Biopsy.
Article in The Journal of clinical endocrinology and metabolism, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Dysregulation of the urea cycle - potential targets for treatment and diagnosis in prostate cancer.Expert reviews in molecular medicine · 2026Review
- Pitfalls of onco-metabolomics: impact of sample integrity on metabolomic investigations in more than 4500 human serum samples from ten different cohorts.Frontiers in molecular biosciences · 2026Article
- Serum metabolomic signatures predict clinical outcomes in advanced non-small cell lung cancer treated with pembrolizumab plus platinum-based chemotherapy.Frontiers in immunology · 2026Article
- Interpretable machine learning for predicting 30-day mortality following intracranial hemorrhage surgery.Frontiers in neurologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
contextDespite clinical suspicion of prostate cancer (PCa), 20% to 25% of patients exhibit a tumor-negative biopsy result.
objectiveThis work aimed to assess the serum metabolic profile of clinically significant (cs) compared to clinically insignificant (ci) PCa or benign (Be) patients.
methodsA total of 1078 serum samples were analyzed. Nuclear magnetic resonance (NMR) spectroscopy was used to quantify 73 metabolites; random forest was used for the model algorithm.
resultsWe identified a 22-metabolite panel, which discriminated csPCa (International Society of Urological Pathology [ISUP] 2-5, n = 328) from ciPCa (ISUP 1, n = 101) and Be patients (negative biopsy, n = 649) with a higher performance when combined with the standard clinical parameters age, prostate-specific antigen (PSA), and percentage free PSA (%fPSA) (area under the curve [AUC] 0.84) than the clinical parameters alone (AUC 0.73). Our study further revealed significant dysregulations of the urea cycle and the choline pathway along with changes in tricarboxylic acid cycle, cholesterol metabolism, and a significant increase of the inflammation marker glycoprotein acetyls B in csPCa patients. In particular, ornithine and dimethylglycine were the 2 most important features to discriminate csPCa from Be + ciPCa with significantly higher ornithine and lower dimethylglycine levels in patients with csPCa (ornithine: 63.7 ± 26.5 µmol/L, dimethylglycine: 12.6 ± 6.3 µmol/L; P < .001) compared to Be + ciPCa patients (ornithine: 50.3 ± 31.6 µmol/L, dimethylglycine: 14.9 ± 7.7 µmol/L).
conclusionThis study discovered a 22-metabolite panel to discriminate patients with csPCa from Be + ciPCa patients when combined with age, PSA, and %fPSA. It may therefore be used as a supportive biomarker to reduce the number of unnecessary biopsies and also to identify novel therapeutic targets in the future.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.